Tests dapagliflozin in adults on peritoneal dialysis for kidney function
Studies whether dapagliflozin is tested for remaining kidney function in dialysis patients.
Plain-language title generated from the registry record
Registry title: Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients
Key facts
- Where
- Chengdu, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 who have been on peritoneal dialysis for 1 to 3 months and still pass some urine. It tests dapagliflozin to protect the kidney function they still have.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Peritoneal dialysis for 1 month to 3 months, with urine output of at least 400ml per day.
- Earlier treatment
- A stable peritoneal dialysis prescription for one month. If you have high blood pressure, a stable maximum tolerated dose of RAAS inhibitors for one month.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Type 1 diabetes, or type 2 diabetes with past diabetic ketoacidosis
- Chronic liver disease, including ALT above 120 IU/L
- Malignant tumors
- Peritonitis within the last month
This trial only enrols participants on dialysis. The registry sentence this rests on: Patients with PD duration between 1 month and 3 months.
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06398977, who can take part
Where in China
- Sichuan Academy of Medical Sciences and Sichuan Provincial People's HospitaChengdu, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sichuan Academy of Medical Sciences
- Trial code
- NCT06398977
- Record updated
- 3 May 2024
- Original description
This study aims to explore the role of dagliflozin in preserving the residual renal function(RRF) in peritoneal dialysis (PD) patients.Read full original descriptionShow less
Dapagliflozin Delays the Loss of Residual Renal Function in Patients Undergoing Peritoneal Dialysis: A Single-Center Randomized Open-Label Study
This study aims to explore the role of dagliflozin in preserving the residual renal function(RRF) in peritoneal dialysis (PD) patients.
Inclusion: Patients with PD duration between 1 month and 3 months; Patients aged between 18 and 75 years; Voluntary signing of informed consent; Stable use of a maximum tolerated dose of RAAS inhibitors for one month if hypertension is present; Daily urine output ≥ 400ml/day; Stable PD prescription for one month.
Exclusion: Patients using the following medications: rifampicin, phenytoin; Patients with a willingness for kidney transplantation within six months; Patients with type 1 diabetes mellitus; Patients with type 2 diabetes mellitus who have experienced diabetic ketoacidosis in the past; Patients with more than 2 episodes of urinary tract infection in the past six months; Patients with severe allergic reactions (rash or angioedema) to Dapagliflozin; Patients with malignant tumors; Patients with a history of pancreatitis or pancreatic transplantation; Patients who experienced acute coronary syndrome or cerebrovascular events within one month; Patients with chronic liver disease, including non-alcoholic fatty liver disease, cirrhosis, ALT > 120 IU/L, and other clinically confirmed severe liver diseases; Hemoglobin level less than 90g/L; Pregnant and lactating women; Patients who developed peritonitis within one month; Patients undergoing combined hemodialysis treatment.